Abstract
Background: Several endoscopic classifications for esophageal adenocarcinoma have been proposed; however, gastric adenocarcinoma is much more common than esophageal or esophagogastric junctional (EGJ) adenocarcinoma in East Asian countries. We, therefore, investigated whether an endoscopic diagnostic algorithm for gastric adenocarcinoma could be used for esophageal or EGJ adenocarcinoma. Methods: One hundred eighteen consecutive patients who underwent endoscopic resection or surgery for intramucosal esophageal or EGJ adenocarcinoma, at the Osaka International Cancer Institute between January 2006 and December 2017, were included in this retrospective study. Their lesions were classified as Siewert type 1 or 2, and the presence of endoscopic magnifying narrow-band imaging findings for diagnosing gastric adenocarcinoma was evaluated. Results: We evaluated 125 adenocarcinomas in 118 patients (29 type 1 and 96 type 2). Demarcation lines (DLs) were seen in 7 (24%) type 1 and 53 (55%) type 2 lesions. Irregular mucosal patterns were present in 2 (7%) type 1 and 22 (23%) type 2 lesions. Irregular vascular patterns were present in 26 (90%) type 1 and 50 (52%) type 2 lesions. According to the magnifying endoscopy diagnostic algorithm for gastric adenocarcinoma, only 7 (24%) type 1 and 52 (54%) type 2 lesions were correctly diagnosed as cancers (p = 0.005). Conclusion: The magnifying endoscopy diagnostic algorithm for gastric cancer may not be useful for esophageal or EGJ adenocarcinomas because of the low visibility of DLs, especially in Siewert type 1 adenocarcinoma.
References
1.
Blot
WJ
, Devesa
SS
, Kneller
RW
, Fraumeni
JF
Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia
. JAMA
. 1991 Mar 13
;265
(10
):1287
–9
. 2.
Hansson
LE
, Sparén
P
, Nyrén
O
. Increasing incidence of carcinoma of the gastric cardia in Sweden from 1970 to 1985
. Br J Surg
. 1993 Mar
;80
(3
):374
–7
. 3.
Bytzer
P
, Christensen
PB
, Damkier
P
, Vinding
K
, Seersholm
N
. Adenocarcinoma of the esophagus and Barrett’s esophagus: a population-based study
. Am J Gastroenterol
. 1999 Jan
;94
(1
):86
–91
.4.
Parfitt
JR
, Miladinovic
Z
, Driman
DK
. Increasing incidence of adenocarcinoma of the gastroesophageal junction and distal stomach in Canada: an epidemiological study from 1964–2002
. Can J Gastroenterol
. 2006 Apr
;20
(4
):271
–6
. 5.
Kusano
C
, Gotoda
T
, Khor
CJ
, Katai
H
, Kato
H
, Taniguchi
H
, et al Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan
. J Gastroenterol Hepatol
. 2008 Nov
;23
(11
):1662
–5
. 6.
Kara
MA
, Ennahachi
M
, Fockens
P
, ten Kate
FJ
, Bergman
JJ
. Detection and classification of the mucosal and vascular patterns (mucosal morphology) in Barrett’s esophagus by using narrow band imaging
. Gastrointest Endosc
. 2006 Aug
;64
(2
):155
–66
.7.
Sharma
P
, Bansal
A
, Mathur
S
, Wani
S
, Cherian
R
, McGregor
D
, et al The utility of a novel narrow band imaging endoscopy system in patients with Barrett's esophagus
. Gastrointest Endosc
. 2006 Aug
;64
(2
):167
–75
. 8.
Goda
K
, Tajiri
H
, Ikegami
M
, Urashima
M
, Nakayoshi
T
, Kaise
M
. Usefulness of magnifying endoscopy with narrow band imaging for the detection of specialized intestinal metaplasia in columnar-lined esophagus and Barrett’s adenocarcinoma
. Gastrointest Endosc
. 2007 Jan
;65
(1
):36
–46
. 9.
Sharma
P
, Bergman
JJ
, Goda
K
, Kato
M
, Messmann
H
, Alsop
BR
, et al Development and validation of a classification system to identify high-grade dysplasia and esophageal adenocarcinoma in Barrett's esophagus using narrow-band imaging
. Gastroenterology
. 2016 Mar
;150
(3
):591
–8
. 10.
Goda
K
, Fujisaki
J
, Ishihara
R
, Takeuchi
M
, Takahashi
A
, Takaki
Y
, et al Newly developed magnifying endoscopic classification of the Japan esophageal society to identify superficial Barrett’s esophagus-related neoplasms
. Esophagus
. 2018 Jun 19
;15
(3
):153
–9
. Available from
11.
Bray
F
, Ferlay
J
, Soerjomataram
I
, Siegel
RL
, Torre
LA
, Jemal
A
. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
. CA Cancer J Clin
. 2018 Nov
;68
(6
):394
–424
. 12.
Tachimori
Y
, Ozawa
S
, Numasaki
H
, Ishihara
R
, Matsubara
H
, Muro
K
, et al Comprehensive registry of esophageal cancer in Japan, 2012
. Esophagus
. 2019 Jul
;16
(3
):221
–45
. 13.
Siewert
JR
, Stein
HJ
. Classification of adenocarcinoma of the oesophagogastric junction
. Br J Surg
. 1998 Nov
;85
(11
):1457
–9
. 14.
Siewert HJS
JR
. Carcinoma of the gastroesophageal junction: classification, pathology and extent of resection
. Dis Esophagus
. 1996
;9
(3
):173
–82
.15.
Yao
K
, Anagnostopoulos
GK
, Ragunath
K
. Magnifying endoscopy for diagnosing and delineating early gastric cancer
. Endoscopy
. 2009 May
;41
(5
):462
–7
. 16.
Muto
M
, Yao
K
, Kaise
M
, Kato
M
, Uedo
N
, Yagi
K
, et al Magnifying endoscopy simple diagnostic algorithm for early gastric cancer (MESDA-G)
. Dig Endosc
. 2016 May
;28
(4
):379
–93
. 17.
Uedo
N
, Ishihara
R
, Iishi
H
, Yamamoto
S
, Yamamoto
S
, Yamada
T
, et al A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy
. Endoscopy
. 2006 Aug
;38
(8
):819
–24
. 18.
Kanemitsu
T
, Yao
K
, Nagahama
T
, Fujiwara
S
, Takaki
Y
, Ono
Y
, et al The vessels within epithelial circle (VEC) pattern as visualized by magnifying endoscopy with narrow-band imaging (ME-NBI) is a useful marker for the diagnosis of papillary adenocarcinoma: a case-controlled study
. Gastric Cancer
. 2014
;17
(3
):469
–77
. 19.
Yoshida
N
, Doyama
H
, Nakanishi
H
, Tsuji
K
, Tominaga
K
, Matsunaga
K
, et al White globe appearance is a novel specific endoscopic marker for gastric cancer: a prospective study
. Dig Endosc
. 2016 Jan
;28
(1
):59
–66
. 20.
Yao
K
, Iwashita
A
, Tanabe
H
, Nishimata
N
, Nagahama
T
, Maki
S
, et al White opaque substance within superficial elevated gastric neoplasia as visualized by magnification endoscopy with narrow-band imaging: a new optical sign for differentiating between adenoma and carcinoma
. Gastrointest Endosc
. 2008
;68
(3
):574
–80
. 21.
Japan Esophageal Society
. Japanese classification of esophageal cancer, 11th edition: part I
. Esophagus
. 2017
;14
(1
):1
–36
. 22.
Japanese Gastric Cancer Association
. Japanese classification of gastric carcinoma: 3rd English edition
. Gastric Cancer
. 2011
;14
(2
):101
–12
. 23.
Yagi
K
, Nozawa
Y
, Endou
S
, Nakamura
A
. Diagnosis of early gastric cancer by magnifying endoscopy with NBI from viewpoint of histological imaging: mucosal patterning in terms of white zone visibility and its relationship to histology
. Diagn Ther Endosc
. 2012
;2012
:954809
. 24.
Kandiah
K
, Chedgy
FJQ
, Subramaniam
S
, Longcroft-Wheaton
G
, Bassett
P
, Repici
A
, et al International development and validation of a classification system for the identification of Barrett’s neoplasia using acetic acid chromoendoscopy: the Portsmouth acetic acid classification (PREDICT)
. Gut
. 2018
;67
:2085
–91
.25.
Uedo
N
, Yoshio
T
, Yoshinaga
S
, Takeuchi
M
, Hatta
W
, Yano
T
, et al Endoscopic gastric mucosal atrophy distinguishes the characteristics of superficial esophagogastric junction adenocarcinoma
. Dig Endosc
. 2017 Apr
;29
(Suppl 2
):26
–36
. © 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
